Hypercoagulable state
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
nonpregnant: no cancer and with an acute medical illness
low molecular weight heparin, fondaparinux, or unfractionated heparin
Thromboprophylaxis should be considered for all patients judged to be at risk for venous thromboembolism (VTE) when admitted to hospital with an acute or critical medical illness (impairing mobility).[105]Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-226S. https://journal.chestnet.org/article/S0012-3692(12)60124-X/fulltext http://www.ncbi.nlm.nih.gov/pubmed/22315261?tool=bestpractice.com [112]Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018 Nov 27;2(22):3198-225. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/30482763?tool=bestpractice.com
Anticoagulant thromboprophylaxis with a low molecular weight heparin (LMWH) such as enoxaparin or dalteparin, low-dose unfractionated heparin (UFH), or fondaparinux is recommended for acutely ill hospitalized medical patients at increased risk of VTE, but without excessive bleeding risk.[105]Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-226S. https://journal.chestnet.org/article/S0012-3692(12)60124-X/fulltext http://www.ncbi.nlm.nih.gov/pubmed/22315261?tool=bestpractice.com LMWH has better pharmacokinetic properties than UFH and is associated with a lower incidence of postoperative heparin-induced thrombocytopenia (HIT).[157]Junqueira DR, Zorzela LM, Perini E. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev. 2017;(4):CD007557. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007557.pub3/full http://www.ncbi.nlm.nih.gov/pubmed/28431186?tool=bestpractice.com LMWH or fondaparinux are generally recommended over UFH.[105]Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-226S. https://journal.chestnet.org/article/S0012-3692(12)60124-X/fulltext http://www.ncbi.nlm.nih.gov/pubmed/22315261?tool=bestpractice.com [112]Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018 Nov 27;2(22):3198-225. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/30482763?tool=bestpractice.com [151]National Institute for Health and Care Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. Aug 2019 [internet publication]. https://www.nice.org.uk/guidance/ng89
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
OR
dalteparin
OR
fondaparinux
Secondary options
heparin
mechanical thromboprophylaxis
Thromboprophylaxis should be considered for all patients judged to be at risk for venous thromboembolism when admitted to hospital with an acute or critical medical illness (impairing mobility).[105]Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-226S. https://journal.chestnet.org/article/S0012-3692(12)60124-X/fulltext http://www.ncbi.nlm.nih.gov/pubmed/22315261?tool=bestpractice.com [112]Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018 Nov 27;2(22):3198-225. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/30482763?tool=bestpractice.com
If the patient is at high risk for major bleeding, mechanical thromboprophylaxis with graduated compression stockings (anti-embolism stockings) or intermittent pneumatic compression is recommended.[105]Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-226S. https://journal.chestnet.org/article/S0012-3692(12)60124-X/fulltext http://www.ncbi.nlm.nih.gov/pubmed/22315261?tool=bestpractice.com [112]Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018 Nov 27;2(22):3198-225. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/30482763?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day while the patient is mobilizing or bathing.
If the bleeding risk decreases, pharmacologic thromboprophylaxis should be considered.
Guideline recommendations may differ by region; refer to local guidelines for further context.
nonpregnant: with cancer
low molecular weight heparin or direct oral anticoagulant or aspirin
Thromboprophylaxis for nonhospitalized (ambulatory) patients with cancer remains controversial and is not routinely recommended unless the patient has additional risk factors or cancer associated with a high-risk of VTE, such as multiple myeloma or pancreatic cancer.[155]Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. 2023 May;34(5):452-67. https://www.annalsofoncology.org/article/S0923-7534(22)04786-X/fulltext http://www.ncbi.nlm.nih.gov/pubmed/36638869?tool=bestpractice.com [158]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer-associated venous thromboembolic disease [internet publication]. https://www.nccn.org/guidelines/category_1 Assessment using a validated VTE risk score (e.g., the Khorana score) may be used to help identify high-risk patients.[158]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer-associated venous thromboembolic disease [internet publication]. https://www.nccn.org/guidelines/category_1
Patients who are receiving systemic chemotherapy and are at high risk for thrombosis (e.g., Khorana score of ≥2 prior to initiating systemic chemotherapy) may be considered for thromboprophylaxis with a direct oral anticoagulant (apixaban or rivaroxaban) or LMWH.[153]Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021 Feb 23;5(4):927-74. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903232 http://www.ncbi.nlm.nih.gov/pubmed/33570602?tool=bestpractice.com [155]Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. 2023 May;34(5):452-67. https://www.annalsofoncology.org/article/S0923-7534(22)04786-X/fulltext http://www.ncbi.nlm.nih.gov/pubmed/36638869?tool=bestpractice.com [159]Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019 Feb 21;380(8):711-9. https://www.nejm.org/doi/10.1056/NEJMoa1814468 http://www.ncbi.nlm.nih.gov/pubmed/30511879?tool=bestpractice.com [160]Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019 Feb 21;380(8):720-8. https://www.nejm.org/doi/10.1056/NEJMoa1814630 http://www.ncbi.nlm.nih.gov/pubmed/30786186?tool=bestpractice.com [161]Kahale LA, Matar CF, Tsolakian I, et al. Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev. 2021 Oct 8;10(10):CD006466. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006466.pub7/full http://www.ncbi.nlm.nih.gov/pubmed/34622445?tool=bestpractice.com
Patients with multiple myeloma who are receiving thalidomide (or its derivatives) with chemotherapy and/or dexamethasone are at high risk for venous thromboembolism and should receive concomitant aspirin (e.g., if ≤1 risk factor) or LMWH (e.g., if ≥2 risk factors), which should be given for the duration of treatment with thalidomide (or its derivatives).[91]Palumbo A, Rajkumar SV, Dimopoulos MA, et al; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb;22(2):414-23. http://www.ncbi.nlm.nih.gov/pubmed/18094721?tool=bestpractice.com [153]Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021 Feb 23;5(4):927-74. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903232 http://www.ncbi.nlm.nih.gov/pubmed/33570602?tool=bestpractice.com [155]Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. 2023 May;34(5):452-67. https://www.annalsofoncology.org/article/S0923-7534(22)04786-X/fulltext http://www.ncbi.nlm.nih.gov/pubmed/36638869?tool=bestpractice.com [156]Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023 Jun 1;41(16):3063-71. https://ascopubs.org/doi/10.1200/JCO.23.00294 http://www.ncbi.nlm.nih.gov/pubmed/37075273?tool=bestpractice.com
The UK guidelines recommend considering thromboprophylaxis for patients with pancreatic cancer receiving chemotherapy. NICE: venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Opens in new window
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
OR
dalteparin
OR
apixaban
OR
rivaroxaban
OR
aspirin
low molecular weight heparin or unfractionated heparin or fondaparinux
Most patients with cancer and an acute medical condition or reduced mobility require pharmacological thromboprophylaxis with LMWH, unfractionated heparin, or fondaparinux during hospitalization.[153]Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021 Feb 23;5(4):927-74. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903232 http://www.ncbi.nlm.nih.gov/pubmed/33570602?tool=bestpractice.com [154]Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334-47. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00160-7/fulltext http://www.ncbi.nlm.nih.gov/pubmed/35772465?tool=bestpractice.com [155]Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. 2023 May;34(5):452-67. https://www.annalsofoncology.org/article/S0923-7534(22)04786-X/fulltext http://www.ncbi.nlm.nih.gov/pubmed/36638869?tool=bestpractice.com [156]Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023 Jun 1;41(16):3063-71. https://ascopubs.org/doi/10.1200/JCO.23.00294 http://www.ncbi.nlm.nih.gov/pubmed/37075273?tool=bestpractice.com [158]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer-associated venous thromboembolic disease [internet publication]. https://www.nccn.org/guidelines/category_1
Hospitalized patients who are undergoing major cancer surgery require pharmacologic thromboprophylaxis with LMWH, unfractionated heparin, or fondaparinux.[153]Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021 Feb 23;5(4):927-74. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903232 http://www.ncbi.nlm.nih.gov/pubmed/33570602?tool=bestpractice.com [155]Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. 2023 May;34(5):452-67. https://www.annalsofoncology.org/article/S0923-7534(22)04786-X/fulltext http://www.ncbi.nlm.nih.gov/pubmed/36638869?tool=bestpractice.com [156]Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023 Jun 1;41(16):3063-71. https://ascopubs.org/doi/10.1200/JCO.23.00294 http://www.ncbi.nlm.nih.gov/pubmed/37075273?tool=bestpractice.com [158]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer-associated venous thromboembolic disease [internet publication]. https://www.nccn.org/guidelines/category_1
Guidelines from the American Society of Clinical Oncology (ASCO) recommend starting thromboprophylaxis preoperatively and continuing postoperatively for at least 7 to 10 days.[156]Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023 Jun 1;41(16):3063-71. https://ascopubs.org/doi/10.1200/JCO.23.00294 http://www.ncbi.nlm.nih.gov/pubmed/37075273?tool=bestpractice.com However, guidelines from the American Society of Hematology recommend starting thromboprophylaxis postoperatively in patients with cancer undergoing a surgical procedure.[153]Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021 Feb 23;5(4):927-74. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903232 http://www.ncbi.nlm.nih.gov/pubmed/33570602?tool=bestpractice.com
Extending thromboprophylaxis with LMWH for up to 4 weeks postoperatively is recommended for patients with cancer undergoing major open or laparoscopic abdominal or pelvic surgery with high-risk features (e.g., obesity, history of VTE, restricted mobility).[153]Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021 Feb 23;5(4):927-74. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903232 http://www.ncbi.nlm.nih.gov/pubmed/33570602?tool=bestpractice.com [155]Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. 2023 May;34(5):452-67. https://www.annalsofoncology.org/article/S0923-7534(22)04786-X/fulltext http://www.ncbi.nlm.nih.gov/pubmed/36638869?tool=bestpractice.com
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
OR
dalteparin
OR
heparin
OR
fondaparinux
mechanical thromboprophylaxis
Treatment recommended for SOME patients in selected patient group
Mechanical thromboprophylaxis (e.g., graduated compression stockings [anti-embolism stockings] or intermittent pneumatic compression) may be added to pharmacologic thromboprophylaxis (particularly in patients at high risk of thrombosis) in hospitalized cancer patients with an acute medical condition or undergoing surgery, but should not be used alone unless pharmacologic thromboprophylaxis is contraindicated in the patients with cancer (e.g., due to active bleeding or a high risk for bleeding).[153]Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021 Feb 23;5(4):927-74. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903232 http://www.ncbi.nlm.nih.gov/pubmed/33570602?tool=bestpractice.com [155]Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. 2023 May;34(5):452-67. https://www.annalsofoncology.org/article/S0923-7534(22)04786-X/fulltext http://www.ncbi.nlm.nih.gov/pubmed/36638869?tool=bestpractice.com [156]Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023 Jun 1;41(16):3063-71. https://ascopubs.org/doi/10.1200/JCO.23.00294 http://www.ncbi.nlm.nih.gov/pubmed/37075273?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day while the patient is mobilizing or bathing.
Guideline recommendations may differ by region; refer to local guidelines for further context.
nonpregnant: undergoing nonorthopedic surgery
early mobilization
For patients undergoing nonorthopedic surgery (i.e., general, gynecologic, or urologic) who are at very low risk for venous thromboembolism, early mobilization is recommended and no pharmacologic prophylaxis is required.[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com
Guideline recommendations may differ by region; refer to local guidelines for further context.
mechanical thromboprophylaxis
For patients undergoing nonorthopedic surgery (i.e., general, gynecologic, or urologic) who are at low risk for venous thromboembolism, mechanical thromboprophylaxis with an intermittent pneumatic compression device is recommended.[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day, while the patient is mobilizing or bathing.
Guideline recommendations may differ by region; refer to local guidelines for further context.
low molecular weight heparin, unfractionated heparin, or mechanical thromboprophylaxis
For patients undergoing general, gynecologic, or urologic surgery who are at moderate risk for venous thromboembolism but not at high risk for major bleeding, a LMWH such as enoxaparin or dalteparin, low-dose unfractionated heparin, or an intermittent pneumatic compression device are recommended.[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day, while the patient is mobilizing or bathing.
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
OR
dalteparin
OR
heparin
mechanical thromboprophylaxis
Patients undergoing general, gynecologic, or urologic surgery who are at moderate risk for venous thromboembolism and at high risk for major bleeding, or for whom the consequences of major bleeding would be severe, should receive mechanical thromboprophylaxis with an intermittent pneumatic compression device.[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com [162]Kakkos SK, Caprini JA, Geroulakos G, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. Cochrane Database Syst Rev. 2016 Sep 7;(9):CD005258. http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD005258.pub3/full http://www.ncbi.nlm.nih.gov/pubmed/27600864?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day, while the patient is mobilizing or bathing.
If the bleeding risk decreases, pharmacologic thromboprophylaxis should be considered.
Guideline recommendations may differ by region; refer to local guidelines for further context.
low molecular weight heparin or unfractionated heparin
Patients undergoing general, gynecologic, or urologic surgery who are at high risk of venous thromboembolism but not at high risk for major bleeding should receive pharmacologic prophylaxis with LMWH or low-dose unfractionated heparin.[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Guideline recommendations may differ by region; refer to local guidelines for further context.
Primary options
enoxaparin
OR
dalteparin
OR
heparin
mechanical thromboprophylaxis
Treatment recommended for ALL patients in selected patient group
Mechanical thromboprophylaxis (graduated compression stockings [anti-embolism stockings] or an intermittent pneumatic compression device) should be added to pharmacologic prophylaxis with LMWH or unfractionated heparin, unless contraindicated.[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day, while the patient is mobilizing or bathing.
Guideline recommendations may differ by region; refer to local guidelines for further context.
low-dose aspirin, fondaparinux, or mechanical thromboprophylaxis
Low-dose aspirin, fondaparinux, or mechanical thromboprophylaxis with an intermittent pneumatic compression device are preferred to no prophylaxis if pharmacologic prophylaxis with LMWH or unfractionated heparin are contraindicated.[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day, while the patient is mobilizing or bathing.
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
aspirin
OR
fondaparinux
mechanical thromboprophylaxis
An intermittent pneumatic compression device is recommended for patients undergoing general, gynecologic, or urologic surgery who are at high risk for venous thromboembolism and at high risk for major bleeding, or those for whom the consequences of bleeding are thought to be severe.[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day, while the patient is mobilizing or bathing.
If the bleeding risk decreases, pharmacologic thromboprophylaxis should be considered.
Guideline recommendations may differ by region; refer to local guidelines for further context.
nonpregnant: undergoing orthopedic surgery
direct oral anticoagulant, low molecular weight heparin, or aspirin
Thromboprophylaxis with a direct oral anticoagulant (apixaban, dabigatran, rivaroxaban), LMWH, or aspirin can be used in patients undergoing total hip or knee arthroplasty.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com [152]Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963238 http://www.ncbi.nlm.nih.gov/pubmed/31794602?tool=bestpractice.com
The American College of Chest Physicians guidelines recommend LMWH as the preferred agent.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com However, subsequent guidance published by the American Society of Hematology recommend direct oral anticoagulants.[152]Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963238 http://www.ncbi.nlm.nih.gov/pubmed/31794602?tool=bestpractice.com
Dabigatran should be initiated 1 to 4 hours postoperatively. A reduced-dose regimen is recommended for those with moderate renal impairment, those aged >75 years, and those on amiodarone. It is not recommended in patients with mechanical prosthetic heart valves.
Apixaban should be given starting 12 to 24 hours postoperatively, provided hemostasis is established.
Rivaroxaban should be given commencing 6 to 10 hours postoperatively, provided hemostasis is established.
Aspirin should be given postoperatively.
An extended course of thromboprophylaxis (e.g., up to 5-6 weeks) is recommended.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com [152]Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963238 http://www.ncbi.nlm.nih.gov/pubmed/31794602?tool=bestpractice.com
Early mobilization lowers risk of venous thromboembolism following total hip arthroplasty replacement.[165]White RH, Gettner S, Newman JM, et al. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med. 2000 Dec 14;343(24):1758-64. https://www.doi.org/10.1056/NEJM200012143432403 http://www.ncbi.nlm.nih.gov/pubmed/11114314?tool=bestpractice.com
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
dabigatran etexilate
OR
apixaban
OR
rivaroxaban
OR
enoxaparin
OR
dalteparin
OR
aspirin
mechanical thromboprophylaxis
Treatment recommended for ALL patients in selected patient group
Mechanical thromboprophylaxis with an intermittent pneumatic compression device can be added to pharmacologic thromboprophylaxis.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com [165]White RH, Gettner S, Newman JM, et al. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med. 2000 Dec 14;343(24):1758-64. https://www.doi.org/10.1056/NEJM200012143432403 http://www.ncbi.nlm.nih.gov/pubmed/11114314?tool=bestpractice.com
An extended course of thromboprophylaxis (e.g., up to 5-6 weeks) is recommended.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com [152]Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963238 http://www.ncbi.nlm.nih.gov/pubmed/31794602?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day, while the patient is mobilizing or bathing.[165]White RH, Gettner S, Newman JM, et al. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med. 2000 Dec 14;343(24):1758-64. https://www.doi.org/10.1056/NEJM200012143432403 http://www.ncbi.nlm.nih.gov/pubmed/11114314?tool=bestpractice.com
Early mobilization lowers risk of venous thromboembolism following total hip arthroplasty.
Guideline recommendations may differ by region; refer to local guidelines for further context.
mechanical thromboprophylaxis
Mechanical thromboprophylaxis with an intermittent pneumatic compression device can be used alone in patients undergoing total hip or knee arthroplasty if risk of bleeding is a concern or there are contraindications to pharmacologic agents.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com
An extended course of thromboprophylaxis (e.g., up to 5-6 weeks) is recommended.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com [152]Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963238 http://www.ncbi.nlm.nih.gov/pubmed/31794602?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day, while the patient is mobilizing or bathing.
Early mobilization lowers risk of venous thromboembolism following total hip arthroplasty.
Guideline recommendations may differ by region; refer to local guidelines for further context.
low molecular weight heparin, unfractionated heparin, fondaparinux, or aspirin
Pharmacologic thromboprophylaxis with LMWH, unfractionated heparin, fondaparinux, or aspirin can be used in patients undergoing hip fracture surgery.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com [152]Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963238 http://www.ncbi.nlm.nih.gov/pubmed/31794602?tool=bestpractice.com
If a delay in surgery is anticipated, LMWH should be started preoperatively between hospital admission and surgery, and at least 12 hours before surgery.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com
Fondaparinux should be started 6 to 8 hours after surgery or on the following day.
Aspirin should be given postoperatively.
An extended course of thromboprophylaxis (e.g., up to 5-6 weeks) is recommended.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com [152]Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963238 http://www.ncbi.nlm.nih.gov/pubmed/31794602?tool=bestpractice.com
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
OR
dalteparin
OR
heparin
OR
fondaparinux
OR
aspirin
mechanical thromboprophylaxis
Treatment recommended for ALL patients in selected patient group
Mechanical thromboprophylaxis with an intermittent pneumatic compression device can be added to pharmacologic thromboprophylaxis in patients undergoing hip fracture surgery if risk of bleeding is a concern.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com
An extended course of thromboprophylaxis (e.g., up to 5-6 weeks) is recommended.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com [152]Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963238 http://www.ncbi.nlm.nih.gov/pubmed/31794602?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day, while the patient is mobilizing or bathing.
Guideline recommendations may differ by region; refer to local guidelines for further context.
mechanical thromboprophylaxis
Mechanical thromboprophylaxis with an intermittent pneumatic compression device can be used alone in patients undergoing hip fracture surgery if risk of bleeding is a concern or there are contraindications to pharmacologic agents.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com
An extended course of thromboprophylaxis (e.g., up to 5-6 weeks) is recommended.[93]Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e278S-325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278063 http://www.ncbi.nlm.nih.gov/pubmed/22315265?tool=bestpractice.com [152]Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963238 http://www.ncbi.nlm.nih.gov/pubmed/31794602?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day, while the patient is mobilizing or bathing.
If the bleeding risk decreases, pharmacologic thromboprophylaxis should be considered.
Guideline recommendations may differ by region; refer to local guidelines for further context.
nonpregnant with major trauma
low molecular weight heparin, unfractionated heparin, or mechanical thromboprophylaxis
Thromboprophylaxis with LMWH, low-dose unfractionated heparin (UFH), or an intermittent pneumatic compression device is recommended in major trauma patients who are at moderate risk for venous thromboembolism.[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com [152]Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963238 http://www.ncbi.nlm.nih.gov/pubmed/31794602?tool=bestpractice.com
Intermittent pneumatic compression alone is recommended (if not contraindicated) for major trauma patients in whom LMWH and low-dose UFH are contraindicated (e.g., due to bleeding risk).[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day while the patient is mobilizing or bathing.
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
OR
dalteparin
OR
heparin
low molecular weight heparin or unfractionated heparin
Pharmacologic thromboprophylaxis with LMWH or low-dose unfractionated heparin is recommended for patients at high risk for venous thromboembolism (e.g., those with acute spinal cord injury, traumatic brain injury, and spinal surgery for trauma) if/when risk of bleeding allows.[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com [152]Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963238 http://www.ncbi.nlm.nih.gov/pubmed/31794602?tool=bestpractice.com
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
OR
dalteparin
OR
heparin
mechanical thromboprophylaxis
Treatment recommended for SOME patients in selected patient group
Mechanical thromboprophylaxis with an intermittent pneumatic compression device can be added to pharmacologic thromboprophylaxis in major trauma patients who are at high risk for venous thromboembolism (e.g., those with acute spinal cord injury, traumatic brain injury, and spinal surgery for trauma), when not contraindicated by lower extremity injury.[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com [152]Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963238 http://www.ncbi.nlm.nih.gov/pubmed/31794602?tool=bestpractice.com [162]Kakkos SK, Caprini JA, Geroulakos G, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. Cochrane Database Syst Rev. 2016 Sep 7;(9):CD005258. http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD005258.pub3/full http://www.ncbi.nlm.nih.gov/pubmed/27600864?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day while the patient is mobilizing or bathing.
Guideline recommendations may differ by region; refer to local guidelines for further context.
mechanical thromboprophylaxis
Mechanical thromboprophylaxis with an intermittent pneumatic compression device alone is recommended (if not contraindicated) for major trauma patients who are at high risk for venous thromboembolism if LMWH and low-dose unfractionated heparin are contraindicated (e.g., due to bleeding risk).[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com
If mechanical thromboprophylaxis is used long-term, compression devices should be removed for only a short time each day while the patient is mobilizing or bathing.
Guideline recommendations may differ by region; refer to local guidelines for further context.
low molecular weight heparin or unfractionated heparin
Treatment recommended for SOME patients in selected patient group
Pharmacologic prophylaxis with LMWH or low-dose unfractionated heparin may be added to mechanical thromboprophylaxis when the risk of bleeding reduces or the contraindication to heparin resolves.[150]Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e227S-77S. http://www.ncbi.nlm.nih.gov/pubmed/22315263?tool=bestpractice.com
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
OR
dalteparin
OR
heparin
pregnant
low molecular weight heparin or unfractionated heparin
Optimal management of asymptomatic pregnant women with hereditary thrombophilia remains controversial due to lack of evidence and differences in guideline recommendations.
The American College of Chest Physicians recommends an individual risk assessment for asymptomatic pregnant women with heritable thrombophilia, with antepartum clinical surveillance or pharmacologic thromboprophylaxis (LMWH or unfractionated heparin) and postpartum thromboprophylaxis for 4 to 6 weeks.[44]Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e691S-736S. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054 http://www.ncbi.nlm.nih.gov/pubmed/22315276?tool=bestpractice.com
The American Society of Hematology recommends antenatal and postpartum thromboprophylaxis for women with a family history of venous thromboembolism who have antithrombin deficiency.[148]Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018 Nov 27;2(22):3317-59. https://www.doi.org/10.1182/bloodadvances.2018024802 http://www.ncbi.nlm.nih.gov/pubmed/30482767?tool=bestpractice.com
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
OR
dalteparin
OR
heparin
clinical surveillance or low molecular weight heparin or unfractionated heparin
Optimal management of asymptomatic pregnant women with hereditary thrombophilia remains controversial due to lack of evidence and differences in guideline recommendations.
The American College of Chest Physicians recommends an individual risk assessment for asymptomatic women with other heritable thrombophilia, with antepartum clinical surveillance or pharmacologic thromboprophylaxis (LMWH or unfractionated heparin) and postpartum thromboprophylaxis for 4 to 6 weeks.[44]Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e691S-736S. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054 http://www.ncbi.nlm.nih.gov/pubmed/22315276?tool=bestpractice.com
The American Society of Hematology guidelines recommend antenatal and postpartum thromboprophylaxis for women who are homozygous for the factor V Leiden mutation or who have combined thrombophilias, regardless of family history of venous thromboembolism (VTE).[148]Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018 Nov 27;2(22):3317-59. https://www.doi.org/10.1182/bloodadvances.2018024802 http://www.ncbi.nlm.nih.gov/pubmed/30482767?tool=bestpractice.com The guidelines also recommend postpartum thromboprophylaxis for women with a family history of VTE who have protein C or protein S deficiency, and for women who are homozygous for the prothrombin gene mutation regardless of family history of VTE.[148]Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018 Nov 27;2(22):3317-59. https://www.doi.org/10.1182/bloodadvances.2018024802 http://www.ncbi.nlm.nih.gov/pubmed/30482767?tool=bestpractice.com
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
OR
dalteparin
OR
heparin
low molecular weight heparin or unfractionated heparin plus aspirin
For women with antiphospholipid syndrome with history of recurrent miscarriage or late pregnancy loss but no prior venous thromboembolism or arterial thrombosis, prophylactic LMWH or unfractionated heparin, in addition to aspirin, is recommended throughout pregnancy.[44]Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e691S-736S. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054 http://www.ncbi.nlm.nih.gov/pubmed/22315276?tool=bestpractice.com
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
or
dalteparin
or
heparin
-- AND --
aspirin
low molecular weight heparin, unfractionated heparin, or mechanical thromboprophylaxis
For women considered at low risk of venous thromboembolism (VTE) after cesarean section, early frequent mobilization is recommended without thromboprophylaxis.[44]Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e691S-736S. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054 http://www.ncbi.nlm.nih.gov/pubmed/22315276?tool=bestpractice.com
For women considered at moderate risk of VTE after cesarean section because of the presence of one major risk factor in addition to pregnancy and cesarean section, pharmacologic thromboprophylaxis (LMWH or unfractionated heparin) or mechanical thromboprophylaxis (e.g., graduated compression stockings [anti-embolism stockings] or intermittent pneumatic compression devices) in those with contraindications to anticoagulants, is recommended while in the hospital following delivery.[44]Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e691S-736S. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054 http://www.ncbi.nlm.nih.gov/pubmed/22315276?tool=bestpractice.com
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
OR
dalteparin
OR
heparin
low molecular weight heparin or unfractionated heparin
For women with multiple additional risk factors for thromboembolism who are undergoing cesarean section and considered to be at high risk of venous thromboembolism, pharmacologic thromboprophylaxis with LMWH or unfractionated heparin is recommended while in the hospital following delivery.[44]Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e691S-736S. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054 http://www.ncbi.nlm.nih.gov/pubmed/22315276?tool=bestpractice.com
Guideline recommendations may differ by region; refer to local guidelines for further context.
Dose varies according to indication; consult local specialist protocol for guidance on dose.
Primary options
enoxaparin
OR
dalteparin
OR
heparin
mechanical thromboprophylaxis
Treatment recommended for ALL patients in selected patient group
Combining mechanical thromboprophylaxis (e.g., graduated compression stockings [anti-embolism stockings] and/or an intermittent pneumatic compression device) with pharmacologic thromboprophylaxis is recommended for women undergoing cesarean section who are at high risk of venous thromboembolism with multiple additional risk factors for thromboembolism.[44]Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e691S-736S. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054 http://www.ncbi.nlm.nih.gov/pubmed/22315276?tool=bestpractice.com
Guideline recommendations may differ by region; refer to local guidelines for further context.
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer